Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatm

Table 6. Combination of “first-generation” immune checkpoint inhibitors IMMUNE CHECKPOINT INHIBITOR PHASE I NCT02118337 AMP-514* Durvalumab/ MEDI4736 Advanced malignancies NCT01975831 Durvalumab/ MEDI4736 Tremelimumab** Breast cancer, ovarian cancer, colorectal cancer, cervical cancer, renal cell carcinoma NCT02261220 NCT01621490 PHASE I/II Nivolumab/Opdivo Ipilimumab Metastatic or unresectable HIV-associated with solid tumors NCT02453620 Metastatic or unresectable breast cancer NCT02000947 Nivolumab/Opdivo Ipilimumab Durvalumab/ MEDI4736 Tremelimumab NCT02374242 Nivolumab/Opdivo Ipilimumab Advanced NSCLC Melanoma, brain metastases Bladder cancer, melanoma NCT02659059 NSCLC Durvalumab/ MEDI4736 Tremelimumab Unresectable mesothelioma NCT02592551 Malignant pleural mesothelioma NCT02519348 Hepatocellular carcinoma NCT02536794 Breast cancer NCT02453282 Durvalumab/ MEDI4736 Tremelimumab EGFT and ALK wild-type advanced or metastatic NSCLC NCT02542293 NSCLC NCT02369874 Recurrent or metastatic squamous cell carcinoma of the head and neck NCT02516241 Bladder cancer NCT02551159 EXPANDED ACCESS TNBC, gastric cancer, pancreatic cancer, SCLC, bladder cancer, ovarian cancer Gastric or gastroesophageal junction adenocarcinoma NCT02553642 NCT02588131 Entinostat (histone deacetylase inhibitor) Hepatocellular carcinoma NCT02340975 PHASE III Advanced or metastatic melanoma NCT02408861 NCT01928394 OTHER THERAPIES Advanced solid tumors NCT01658878 PHASE II CONDITION Squamous cell carcinoma of the head and neck NCT01844505 Nivolumab/Opdivo Ipilimumab Unresectable or metastatic melanoma NCT02186249 Nivolumab/Opdivo Ipilimumab Malignant melanoma *ANTI-PD-1, **ANTI-CTLA-4 Another checkpoint, TIM-3, inhibits T helper 1

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatm | Page 12